Buy AIZ now: trend is bullish (MACD expanding, moving averages stacked bullish) and fundamentals/Street targets imply ~5%–9% upside vs. $241.
Options positioning is supportive (put/call OI 0.49 = more calls than puts), suggesting bullish/constructive sentiment.
Near-term path: price is close to resistance (R1 ~$243, R2 ~$246), so a push toward ~$246 then ~$254 is the cleanest upside roadmap into earnings (Feb 10).
Momentum: MACD histogram +0.202 and expanding → bullish momentum is strengthening.
RSI(6): ~69.96 → momentum is strong and nearing overbought, but not flashing a hard reversal signal.
Key levels: Pivot 237.93 (important near-term support). Resistance R1 243.06 then R2 246.22; supports S1 232.80 then S2 229.63.
Pattern-based odds (next periods): 50% chance of a small gain next day (+0.9%), modest +0.42% next week, but model implies softer month (-1.96%)—suggesting nearer-term strength with a less certain 1-month follow-through.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Sentiment via positioning: Open interest put/call ratio 0.49 is bullish/constructive (calls outweigh puts).
Activity: Options volume is effectively 0 today (no meaningful volume read-through); open interest exists (calls 591 vs puts 290).
Volatility: IV(30d) ~21.56 vs HV ~22.5; IV percentile ~27 and IV rank ~4.3 → options are relatively inexpensive vs the past year.
Politicians / influential figures: No recent congress trading data available; no politician buy/sell signal to confirm momentum.
Technical Summary
Sell
3
Buy
9
Positive Catalysts
Fundamentals momentum: 2025/Q3 showed strong YoY growth (revenue +8.57%, EPS +103.14%, net income +98.51%), supporting continuation narratives.
Analyst support: Multiple firms raised price targets recently (cluster of upward revisions), which often reinforces institutional confidence.
Corporate governance/news: New board appointment (Lynn Blake) with deep investment management background can be perceived as a quality/oversight positive.
Event catalyst ahead: QDEC 2025 earnings on 2026-02-10 (after hours) could re-rate the stock if results/guide confirm momentum (Street EPS est. ~5.55).
Neutral/Negative Catalysts
raises the odds of short-term chop/pullback even within an uptrend.
Overall read: growth + margin/profit acceleration indicate strong operational momentum going into the next earnings cycle.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: Clear run of price-target increases (UBS to $257; BMO to $246; Morgan Stanley to $248; Keefe Bruyette to $254; Piper Sandler to $264) with mostly Buy/Outperform/Overweight stances; one notable Equal Weight (Morgan Stanley).
Wall Street pros: consistent upward revisions post-Q3 beat, expectations for positive momentum across business units, and confidence in pipeline/near-term execution.
Wall Street cons: acknowledgement of potential insurance-cycle softening into 2026 (more cautious framing), and higher share price reducing repurchase accretion (a mild headwind to EPS boost from buybacks).
Wall Street analysts forecast AIZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AIZ is 255.67 USD with a low forecast of 246 USD and a high forecast of 265 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast AIZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AIZ is 255.67 USD with a low forecast of 246 USD and a high forecast of 265 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 242.460
Low
246
Averages
255.67
High
265
Current: 242.460
Low
246
Averages
255.67
High
265
Piper Sandler
Overweight
maintain
$252 -> $264
AI Analysis
2025-12-19
Reason
Piper Sandler
Price Target
$252 -> $264
AI Analysis
2025-12-19
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on Assurant to $264 from $252 and keeps an Overweight rating on the shares. The firm is generally above consensus for most of insurtech. The claims environment has been strong, while AI and automation in insurance is borne out and seen directly in this group.
Keefe Bruyette
Outperform
maintain
$248 -> $254
2025-11-20
Reason
Keefe Bruyette
Price Target
$248 -> $254
2025-11-20
maintain
Outperform
Reason
Keefe Bruyette raised the firm's price target on Assurant to $254 from $248 and keeps an Outperform rating on the shares. The firm still expects positive momentum across the business units, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for AIZ
